For those that don’t know, Cassava Sciences is a clinical stage biotech company that is in the process of developing their answer to Alzheimer’s. They are currently in Phase III of the drug trials with results coming out sometime late Q4/early next year. With potential success of the trial right around the corner, this is a boom/bust type of opportunity.
Here are a few things to consider :
1) SAVA has coordinated directly with the FDA in the design and execution of the drug trials.
2) SAVA in the last 6 months has added 3 BOD with varying specialties that provides further confidence of investment in the company in the future.
3) In the last 10 days, several insiders have exercised thousands of warrants that equates out to millions of dollars worth of stock purchases.
The results so far in the drug have been very positive and leads investors confident in overall approval.
The bears will point to accusations of “fraud”. All of which are of no merit and have been debunked in various twitter threads/discords. Make no mistake, there is risk in the stock, but the upside is a rare opportunity.
Leave a Reply